

## Special Issue

# Antibody Response of Vaccines to SARS-CoV-2

### Message from the Guest Editor

The COVID-19 pandemic has highlighted health and socioeconomic inequalities around the world. Several COVID-19 vaccines have been approved for human use worldwide. The past two years of the pandemic have allowed researchers a better understanding of SARS-CoV-2 and the antibody responses elicited by vaccines and natural infection. All currently approved vaccines utilize the SARS-CoV-2 spike protein and elicit IgG responses. Therefore, this Special Issue, “Antibody Response of Vaccines to SARS-CoV-2”, of Vaccines aims to present the latest findings to improve antibody responses, the type of antibody responses required for long-term protection, and future perspectives on new vaccine strategies and targets. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- immunogenicity and efficacy of licensed vaccines
- New generations of vaccines against COVID-19
- Vaccination strategies for particular populations
- Antibody isotypes and their locations as well as roles in protection
- Immunological correlate of protection

I look forward to receiving your contributions.

---

### Guest Editor

Dr. Drishya Kurup

Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA

---

### Deadline for manuscript submissions

closed (1 May 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/127220](https://mdpi.com/si/127220)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).